

Comparative Study of RP-HPLC and UV Spectrophotometric Methods for Assay of Balofloxacin in Pharmaceutical Dosage Forms



Pharma

KEYWORDS : Balofloxacin; UV spectrophotometry; RP-HPLC; Validation

Sanjay Pai PN

Department of Pharmaceutical Analysis (Quality Assurance Group), Goa College of Pharmacy, 18th June Road, Panaji, Goa – 403 001, India

Ameet Kolwalkar

Department of Pharmaceutical Analysis (Quality Assurance Group), Goa College of Pharmacy, 18th June Road, Panaji, Goa – 403 001, India

Anusha Palekar

Department of Pharmaceutical Analysis (Quality Assurance Group), Goa College of Pharmacy, 18th June Road, Panaji, Goa – 403 001, India

ABSTRACT

Two simple, precise, accurate and economical RP-HPLC and UV spectrophotometric methods were developed and validated for the estimation of balofloxacin in the pharmaceutical dosage forms. The chromatographic separation was achieved isocratically on ACCLAIMTM 120 C18 column (5 µm, 4.6×250 mm) and methanol: 0.25 M phosphoric acid 80:20(v/v) as the mobile phase, at a flow rate of 1ml/min using isocratic elution. Detection was carried out at 293 nm. The retention time was found to be 2.7 min. The linearity range was found to be 5-50 µg/ml with r2 value of 0.9999. Accuracy was determined at 3 different levels by recovery studies and showed percent recovery ranging from 96.70-101.04%. UV spectrophotometric method was developed using 0.1 N HCl as the solvent and absorbance was recorded at λ_{max} of 293 nm. Beer's law was obeyed in the concentration range of 2-14 µg/ml with r2 value of 0.9975. Accuracy was determined by recovery studies and showed percent recovery ranging from 99.92-101.20%. The developed methods can be used in QC laboratory for routine analysis to ensure the identity, purity, and performance of the drug product.

INTRODUCTION

Balofloxacin, 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylaminopiperidine-1-yl)-4-oxoquinoline-3-carboxylic acid is a new generation fluoroquinolone antibiotic and has a broader spectrum of activity and reduced toxicity than other fluoroquinolones. It is prescribed for infective ophthalmitis, chronic bronchitis, community-acquired pneumonia, skin and urinary tract infections¹. Its quantitative determination in pharmaceutical formulations is important to guarantee the desired therapeutic effects. Review of literature revealed that balofloxacin has been analysed by a RP-HPLC²⁻⁶ and spectrophotometric⁷⁻¹¹ methods. The aim of the present study was to develop, validate and compare RP-HPLC and UV spectrophotometric methods for the analysis of balofloxacin in pharmaceutical formulations.

Materials and Methods

Reagents and chemicals:

Gift sample of balofloxacin was provided by Cirex Pharmaceuticals (P) Ltd, Hyderabad, India. HCl LR, Methanol HPLC grade and milli Q water were used. Sample analysis was performed on Baloforce™ 100 mg tablets purchased from local market.

Instrumentation:

Thermo Scientific HPLC, model Ultimate 3000 equipped with variable wavelength detector was used. Sample injection was manual, through the rheodyne injection valve with 20 µl loop. The output signal was monitored and integrated using Chromeleon software. UV method was performed on UV-visible double beam spectrophotometer, LABINDIA ANALYTICAL UV 3000* and the output signal was monitored and integrated using UV WIN software.

Chromatographic conditions:

ACCLAIM™ C18 column (250×4.6 mm, 5 µm) was used for separation. The mobile phase containing methanol: 0.25 M phosphoric acid (80:20) was delivered at the flow rate of 1 ml/min with detection at wavelength 293 nm. The injection volume was 20 µl. The run time was 10 min.

Spectrophotometric conditions:

UV method was performed on UV Spectrophotometer, LABINDIA ANALYTICAL UV 3000*. Solvent used was 0.1 N HCl with detection at 293 nm.

Standard stock solution:

For HPLC method, Standard stock solution of balofloxacin was prepared by dissolving 25 mg in 25 ml mobile phase, methanol : 0.25 M phosphoric acid (80:20) v/v. From the stock solution, working standard was prepared by appropriate dilution to 10 ml with mobile phase.

For UV spectrophotometric method, Standard stock solution of balofloxacin was prepared by dissolving 10 mg in 10 ml 0.1 N HCl. Working standard was prepared by appropriate dilution to 10 ml with solvent.

Selection of analytical wavelength:

For HPLC and UV methods, working standard solution prepared from the standard stock solution was scanned in the wavelength range from 200-400 nm to finalize the analytical wavelength for the present study.

Application of the methods to the analysis of balofloxacin in the pharmaceutical dosage form:

For HPLC method, Tablets, twenty in number (Baloforce™) were finely powdered and an accurately weighed quantity of powder equivalent to 10 mg of balofloxacin was transferred to 10 ml volumetric flask and extracted with 10 ml mobile phase by shaking it for 15 min, filtered through whatmann No. 1 paper. From this solution, 0.2 ml was transferred to 10 ml volumetric flask and volume made up to obtain working sample solution of the drug.

For UV method, tablet powder equivalent to 10 mg of balofloxacin was transferred to 10 ml volumetric flask and extracted with 10 ml 0.1 N HCl by shaking it for 15 min, filtered through whatmann No. 1 paper. From this solution, 1 ml was transferred to 10 ml volumetric flask and volume made up to obtain working sample solution of the drug. From the working standard solution, 0.6 ml was diluted to 10 ml with the solvent and its absorbance was measured at the selected wavelength. The content of balofloxacin in sample solution of tablet was calculated using proposed method.

Forced degradation studies:

For HPLC method, forced degradation studies for 8 hr duration were performed by subjecting the standard drug to acid hydrolysis (1N HCl) and base hydrolysis (1N NaOH) under reflux; elevat-

ed temperature 70°C, oxidation (3% H₂O₂) and UV light.

Method validation:

The methods were validated as per ICH guidelines¹². Specificity of the method was assessed by comparing the Rt and peak area of standard balofloxacin and sample, both injected at test concentration of 10 µg/ml. Linearity was determined for HPLC and UV method. The graph was obtained by plotting the area vs. concentration for HPLC and absorbance vs. concentration for UV method. Method accuracy for HPLC and UV was performed by spiking the known amounts of drug to the previously analyzed sample at three levels of 80 to 120% of the nominal analyte concentration. The percentage recovery in each case was calculated. Intra-day precision of six replicates on same day and on two different days for inter-day precision was done. Results are expressed as %RSD of the measurements. Robustness was determined by making small deliberate changes in the pH of the mobile phase ± 0.2 of the optimized pH, flow rate ±0.2 ml and mobile phase composition ±5% of the optimized ratio.

RESULTS AND DISCUSSION

The aim of this study was to develop and validate simple, accurate and sensitive RP-HPLC and UV spectrophotometric methods for the estimation of balofloxacin in pharmaceutical dosage forms. For HPLC method, chromatographic parameters such as mobile phase ratio, pH, and flow rate and detection wavelength were studied. Mobile phase containing methanol: 0.25 M phosphoric acid 80:20 (v/v) with a flow rate of 1 ml/min was selected as the optimized mobile phase since the drug chromatogram showed good peak shape, and symmetry with the Rt of 2.7 min. Since the λ_{max} of the drug in the mobile phase was found to be 293 nm, it was selected as detection wavelength. For UV spectrophotometry λ_{max} was determined as 293 nm.

Table 1: Validation parameters and Results of sample analysis

Parameters	HPLC	UV Spectrophotometry
Theoretical plates	4726	-----
Asymmetric factor	1.13	-----
Retention Time (min)	2.70	-----
Linearity (µg/ml)	5-50	2-14
Regression Equation	y = 1.9469x + 0.2162	y = 0.0499x + 0.0288
Slope (m)	1.9469	0.0499
Intercept (c)	0.2162	0.0288
Correlation coefficient	0.9999	0.9975
% RSD	Intraday-1.277631 Interday-0.980025	Intraday-0.3875 Interday-1.2909
Sample analysis (mg) (Label claim 100 mg)	102.39	104.15

Table 2: Robustness data (HPLC method)

Parameter	Optimized conditions	Variation	Observations	
			Rt (min)	% assay
Mobile phase Ratio	80:20	75:25	2.920	102.10
		80:20	2.710	98.86
		85:15	2.617	100.15
Mobile phase pH	2.9	2.7	2.747	100.15
		2.9	2.710	98.86
		3.1	2.890	100.90
Flow rate (in ml)	1.0	0.8	2.230	106.67
		1.0	2.710	99.70
		1.2	3.333	94.44

Table 3: Stability profile (from HPLC method)

Stress degradation conditions	% Degradation of Balofloxacin
Thermal	1.52
Photo	1.72
Oxidation	3.65
Acid	4.34
Base	1.10

For RP-HPLC method, system suitability parameters were determined using standard solutions and are summarized in Table 1. The values obtained suggest the suitability of the system for the analysis of the drug in the dosage form. For RP-HPLC and UV method, calibration curves were constructed by plotting the peak area (y-axis) to the concentration (x-axis) and absorbance at 293 nm (y-axis) to the concentration (x-axis) respectively. The response was found to be linear with a correlation coefficient of 0.999 and 0.9975 respectively, showing good correlation existing between area of the peak (or absorbance in UV analysis) and concentration. The robustness of the HPLC method was studied by changing the chromatographic conditions slightly and the results indicated that the proposed HPLC method was robust (Table 2). The results of forced degradation studies are presented in Table 3. The developed methods were successfully applied for the determination of balofloxacin in the pharmaceutical dosage form and the results of the assay were comparable with the corresponding labeled amounts. High recovery values (HPLC and UV) and no additional peaks in the chromatogram indicate that the developed methods are accurate and specific and can be used for the routine analysis of balofloxacin in the pharmaceutical dosage forms.

CONCLUSION

The RP-HPLC method gives good peak shape, asymmetry with a short analysis time. Both the methods are validated and are simple, sensitive, accurate and precise. The results obtained from UV spectrophotometric method using 0.1 N hydrochloric acid as solvent was comparable to the results of HPLC analysis of balofloxacin. Also the degradation ability of balofloxacin was extremely negligible and under stress conditions was demonstrated to be under 4% indicating the usefulness of UV spectrophotometric method. This indicates that the UV spectrophotometric using 0.1 N hydrochloric acid method for analysis of balofloxacin is comparable to HPLC method and could be best choice in routine analysis of balofloxacin tablets in routine analysis.

ACKNOWLEDGEMENTS

Authors wish to thank Cirex Pharmaceuticals (P) Ltd, Hyderabad, India for providing the gift sample of balofloxacin. The authors are also thankful to Dr. G.K. Rao, Principal, Goa College of Pharmacy for supporting research activities at the department.

REFERENCE

1. Balofloxacin-Drug Information.[Internet] [cited 2013 Sept 5] Available from: <http://www.medindia.net> | 2. Nyola N, Jeyabalan G. Estimation of balofloxacin in active pharmaceutical ingredient and pharmaceutical formulations by different analytical methods. *Novel science Int. J. Pharm. Sci.* 2012; 1(7):425-29. | 3. Ravisankar P, Devala RG, Devadasu C, Gopalareddy P Srinivasa BP Afsal BSK et al. A novel validated RP-HPLC method for the determination of balofloxacin in bulk and pharmaceutical dosage forms. *Int. J. Pharm. Ind.Res.* 2013; 3(2):127-36. | 4. Naga RP, Devala RG, Rajendra PY. Development and validation of a Reverse Phase -HPLC method for the determination of balofloxacin in bulk and pharmaceutical dosage forms. *Drug Invention Today* 2012; 4(12):655-58.5. | 5. Ravisankar P, Devala RG. Rapid simultaneous separation of six fluoroquinolone antibacterial- levofloxacin, prulifloxacin, gatifloxacin, sparfloxacin, moxifloxacin and balofloxacin by RP-HPLC:application to balofloxacin determination in pharmaceutical dosage forms. *Int. J. Adv. Pharm. Res.* 2013; 4(5):1778-91. | 6. Bian Z, Tian Y, Xu F, Cao X. High performance liquid chromatography- electrospray ionization mass spectrometric determination of balofloxacin in human plasma and its pharmacokinetics. *J.chromatogr B Analyt Technol Biomed Life* [Internet]. 2007 [Cited on 2014Feb 18]; 850(1):68-73. Available from: <http://www.sciencedirect.com/science/article/pii/S157002306009329> | 7. Shreya N, Sanjay Pai PN. Spectrophotometric determination of balofloxacin by ion-pair complexation reaction in the bulk and tablet dosage forms. *Asian J. Pharm. Clin. Res.* 2013; 6(4):22-24. | 8. Shreya N, Sanjay Pai PN. Development and validation of a new spectrophotometric method for the determination of balofloxacin in pharmaceutical dosage forms. *J. Pharm. Sci. Inov.* 2013; 2(4):59-61. | 9. Shreya N, Sanjay Pai PN. Analytical methods for determination of balofloxacin in tablets. *Int. J. Sci. Res.* 2013; 2(8):66-68. | 10. Punam RT, Vandana BP. Development and validation of analytical methodfor estimation of balofloxacin in bulk and pharmaceutical dosage form. *Int. J. Pharm. Tech. Res.* 2011; 2(3):1938-41. | 11. Seetharaman R, Lakshimi KS, Dinesh KB, Hariprasad G Kumud Rr. Determination of balofloxacin in pharmaceutical by zero, first, and second order derivative spectrophotometric methods. *Int. J. Res. Pharm. Sci.* 2011; 2(3):438-44. | 12. International Conference on Harmonization. Validation of analytical procedures: Methodology Q2B, International Conference on Harmonization. Geneva: IFFPMA; 1997. |